ProQR Therapeutics (NASDAQ:PRQR) Receives Consensus Rating of “Buy” from Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR) have received a consensus recommendation of “Buy” from the five ratings firms that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $7.60.

Several equities research analysts have issued reports on PRQR shares. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $6.00 to $14.00 in a report on Tuesday, October 29th. Finally, JMP Securities restated a “market outperform” rating and set a $8.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th.

ProQR Therapeutics Stock Down 12.6 %

Shares of PRQR opened at $2.57 on Thursday. ProQR Therapeutics has a twelve month low of $1.61 and a twelve month high of $4.62. The stock has a market capitalization of $209.92 million, a P/E ratio of -8.03 and a beta of 0.24. The company has a 50 day moving average of $3.45 and a 200-day moving average of $2.41.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRQR. Privium Fund Management B.V. raised its position in shares of ProQR Therapeutics by 4.4% in the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock valued at $9,208,000 after purchasing an additional 236,279 shares during the period. OneDigital Investment Advisors LLC grew its stake in ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares during the period. 32.65% of the stock is owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).